KLOTHO Antibody | MyBioSource MBS150338 product information

product summary

company name :

MyBioSource

product type :

antibody

product name :

KLOTHO Antibody

catalog :

MBS150338

quantity :

0.1 mg

price :

345 USD

clonality :

polyclonal

host :

rabbit

conjugate :

nonconjugated

reactivity :

human, mouse, rat

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, enzyme immunoassay

more info or order :

MyBioSource product webpage

product information

catalog number :

MBS150338

products type :

Antibody

products full name :

KLOTHO Antibody

products short name :

KLOTHO

products name syn :

KLOTHO; Klotho; klotho

other names :

klotho; Klotho; klotho; klotho

products gene name :

other gene names :

KL; KL

uniprot entry name :

KLOT_HUMAN

clonality :

Polyclonal

isotype :

IgG

host :

Rabbit

reactivity :

Human, Mouse, Rat

sequence length :

1012

specificity :

Three isoforms of KLOTHO are known to exist.

purity :

KLOTHO Antibody is affinity chromatography purified via peptide column.

form :

Liquid

concentration :

1 mg/mL

storage stability :

KLOTHO antibody can be stored at 4 degree C for three months and -20 degree C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

tested application :

ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)

app notes :

KLOTHO antibody can be used for detection of KLOTHO by Western blot at 1 - 2 mug/mL. Antibody can also be used for immunohistochemistry starting at 2.5 mug/mL. For immunofluorescence start at 20 mug/mL.

other info1 :

Conjugate: Unconjugated. Immunogen: KLOTHO antibody was raised against a 16 amino acid synthetic peptide near the center of human KLOTHO. Buffer: KLOTHO Antibody is supplied in PBS containing 0.02% sodium azide.

products description :

KLOTHO Antibody: KLOTHO is the systemic anti-aging hormone within the glycosidase1 superfamily. It encodes a type I membrane protein that is abundant in the kidney and brain. In mice, a deficiency in KLOTHO expression leads to various systemic phenotypes resembling human aging such as arteriosclerosis, osteoporosis, and skin atrophy together with growth retardation, short life-span and infertility. Transgenic mice overexpressing KLOTHO have an extended life span by inhibiting insulin/IGF1 signaling. KLOTHO is involved in the regulation of calcium/phosphorus homeostasis by inhibiting the synthesis of active vitamin D and identified as a potential tumor suppressor.

ncbi gi num :

24497614

ncbi acc num :

NP_004786

ncbi gb acc num :

NM_004795.3

uniprot acc num :

Q9UEF7

ncbi mol weight :

Predicted: 111 kDa. Observed: 106 kDa

ncbi pathways :

Adaptive Immune System Pathway (366160); Constitutive PI3K/AKT Signaling In Cancer Pathway (685535); DAP12 Interactions Pathway (685549); DAP12 Signaling Pathway (685550); Disease Pathway (530764); Downstream Signal Transduction Pathway (106385); Downstream Signaling Events Of B Cell Receptor (BCR) Pathway (576250); Downstream Signaling Of Activated FGFR Pathway (160957); Endocrine And Other Factor-regulated Calcium Reabsorption Pathway (213307); Endocrine And Other Factor-regulated Calcium Reabsorption Pathway (213276)

ncbi summary :

This gene encodes a type-I membrane protein that is related to beta-glucosidases. Reduced production of this protein has been observed in patients with chronic renal failure (CRF), and this may be one of the factors underlying the degenerative processes (e.g., arteriosclerosis, osteoporosis, and skin atrophy) seen in CRF. Also, mutations within this protein have been associated with ageing and bone loss. [provided by RefSeq, Jul 2008]

uniprot summary :

Klotho: May have weak glycosidase activity towards glucuronylated steroids. However, it lacks essential active site Glu residues at positions 239 and 872, suggesting it may be inactive as a glycosidase in vivo. May be involved in the regulation of calcium and phosphorus homeostasis by inhibiting the synthesis of active vitamin D. Essential factor for the specific interaction between FGF23 and FGFR1. Defects in KL are a cause of hyperphosphatemic familial tumoral calcinosis (HFTC). A severe metabolic disorder that manifests with hyperphosphatemia and massive calcium deposits in the skin and subcutaneous tissues. Some patients manifest recurrent, transient, painful swellings of the long bones associated with the radiographic findings of periosteal reaction and cortical hyperostosis and absence of skin involvement. Belongs to the glycosyl hydrolase 1 family. Klotho subfamily. 2 isoforms of the human protein are produced by alternative splicing. Protein type: Membrane protein, integral; Hydrolase; EC 3.2.1.31. Chromosomal Location of Human Ortholog: 13q12. Cellular Component: extracellular space; integral to plasma membrane; plasma membrane; integral to membrane; extracellular region. Molecular Function: vitamin D binding; signal transducer activity; fibroblast growth factor binding; beta-glucuronidase activity; beta-glucosidase activity; hormone activity; fibroblast growth factor receptor binding. Biological Process: epidermal growth factor receptor signaling pathway; calcium ion homeostasis; fibroblast growth factor receptor signaling pathway; phosphoinositide-mediated signaling; nerve growth factor receptor signaling pathway; carbohydrate metabolic process; energy reserve metabolic process; insulin receptor signaling pathway; innate immune response; positive regulation of bone mineralization; acute inflammatory response; aging. Disease: Tumoral Calcinosis, Hyperphosphatemic, Familial

size1 :

0.1 mg

price1 :

345 USD

more info or order :

MyBioSource product webpage